Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy

Cancer Epidemiology

Volumn 34, Issue 5, 2010, Pages 634-638

  Henríquez Hernández, Luis Alberto ^a,b   Murias Rosales, Adolfo ^b,c   González Hernández, Ana ^b,d   de León, Antonio Cabrera ^b,d   Díaz Chico, Nicolás ^a,b   Fernández Pérez, Leandro ^a,b  

^a UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^b Madrid Spain   (Spain)

^c HOSPITAL UNIVERSITARIO INSULAR DE GRAN CANARIA   (Spain)

^d HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Adverse reaction; Breast cancer; MTHFR; Neoadjuvant chemotherapy; P53; Polymorphism; Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; ALLELE; ARTICLE; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CODON; DIARRHEA; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CODON; CYCLOPHOSPHAMIDE; FLUOROURACIL; GENES, P53; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; NEOADJUVANT THERAPY; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; THYMIDYLATE SYNTHASE;

EID: 77957240834     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2010.06.013     Document Type: Article

References (44)

1. Kamangar F., Dores G.M., Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006, 24:2137-2150.
2. Sachelarie I., Grossbard M.L., Chadha M., Feldman S., Ghesani M., Blum R.H. Primary systemic therapy of breast cancer. Oncologist 2006, 11:574-589.
3. Fisher B., Brown A., Mamounas E., Wieand S., Robidoux A., Margolese R.G., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997, 15:2483-2493.
4. Sharp L., Little J. Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 2004, 159:423-443.
5. Marsh S., McLeod HL Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet 2006, 15(Spec No. 1):R89-R93.
6. Kawakami K., Omura K., Kanehira E., Watanabe Y. Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 1999, 19:3249-3252.
7. Russo A., Corsale S., Cammareri P., Agnese V., Cascio S., Di Fede G., et al. Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy. J Cell Physiol 2005, 204:742-749.
8. Marsh S. Impact of pharmacogenomics on clinical practice in oncology. Mol Diagn Ther 2007, 11:79-82.
9. Etienne-Grimaldi M.C., Francoual M., Formento J.L., Milano G. Methylenetetrahydrofolate reductase (MTHFR) variants and fluorouracil-based treatments in colorectal cancer. Pharmacogenomics 2007, 8:1561-1566.
10. Huang R.S., Ratain M.J. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009, 59:42-55.
11. Akoglu B., Kindl P., Weber N., Trojan J., Caspary W.F., Faust D. Polymorphisms in the methylenetetrahydrofolate reductase gene are determinant for vascular complications after liver transplantation. Eur J Clin Nutr 2008, 62:430-435.
12. Przekop P.R., Tulgan H., Przekop A.A., Glantz M. Adverse drug reaction to methotrexate: pharmacogenetic origin. J Am Osteopath Assoc 2006, 106:706-707.
13. Gemmati D., Ongaro A., Tognazzo S., Catozzi L., Federici F., Mauro E., et al. Methylenetetrahydrofolate reductase C677T and A1298C gene variants in adult non-Hodgkin's lymphoma patients: association with toxicity and survival. Haematologica 2007, 92:478-485.
14. Borresen-Dale A.L. TP53 and breast cancer. Hum Mutat 2003, 21:292-300.
15. Papadakis E.N., Dokianakis D.N., Spandidos D.A. p53 codon 72 polymorphism as a risk factor in the development of breast cancer. Mol Cell Biol Res Commun 2000, 3:389-392.
16. Dumont P., Leu J.I., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365.
17. Xu Y., Yao L., Ouyang T., Li J., Wang T., Fan Z., et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005, 11:7328-7333.
18. Leonessa F., Clarke R. ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 2003, 10:43-73.
19. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000, 97:3473-3478.
20. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., Gottesman M.M. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007, 67:9609-9612.
21. Zubor P., Lasabova Z., Hatok J., Stanclova A., Danko J. A polymorphism C3435T of the MDR-1 gene associated with smoking or high body mass index increases the risk of sporadic breast cancer in women. Oncol Rep 2007, 18:211-217.
22. Cabrera de Leon A., Rodriguez Perez Mdel C., Almeida Gonzalez D., Dominguez Coello S., Aguirre Jaime A., Brito Diaz B., et al. [Presentation of the "CDC de Canarias" cohort: objectives, design and preliminary results]. Rev Esp Salud Publica 2008, 82:519-534.
23. Nilsson G., Skytting B., Xie Y., Brodin B., Perfekt R., Mandahl N., et al. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res 1999, 59:3180-3184.
24. Hayes D.F., Thor A.D. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002, 29:231-245.
25. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
26. Henriquez-Hernandez L.A., Murias-Rosales A., Hernandez Gonzalez A., Cabrera De Leon A., Diaz-Chico B.N., Mori De Santiago M., et al. Gene polymorphisms in TYMS, MTHFR, p53 and MDR1 as risk factors for breast cancer: a case-control study. Oncol Rep 2009, 22:1425-1433.
27. Nogueira J.A., Ono-Nita S.K., Nita M.E., de Souza M.M., do Carmo E.P., Mello E.S., et al. 249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients. BMC Cancer 2009, 9:204.
28. Shimasaki N., Mori T., Torii C., Sato R., Shimada H., Tanigawara Y., et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2008, 30:347-352.
29. Zarate R., Gonzalez-Santigo S., de la Haba J., Bandres E., Morales R., Salgado J., et al. GSTP1 and MTHFR polymorphisms are related with toxicity in breast cancer adjuvant anthracycline-based treatment. Curr Drug Metab 2007, 8:481-486.
30. Ongaro A., De Mattei M., Della Porta M.G., Rigolin G., Ambrosio C., Di Raimondo F., et al. Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 2009, 94:1391-1398.
31. Sharma R., Hoskins J.M., Rivory L.P., Zucknick M., London R., Liddle C., et al. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clin Cancer Res 2008, 14:817-825.
32. Chua W., Goldstein D., Lee C.K., Dhillon H., Michael M., Mitchell P., et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009, 101:998-1004.
33. Toffoli G., Veronesi A., Boiocchi M., Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann Oncol 2000, 11:373-374.
34. Gusella M., Frigo A.C., Bolzonella C., Marinelli R., Barile C., Bononi A., et al. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer. Br J Cancer 2009, 100:1549-1557.
35. Kantar M., Kosova B., Cetingul N., Gumus S., Toroslu E., Zafer N., et al. Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 2009, 50:912-917.
36. Afzal S., Jensen S.A., Vainer B., Vogel U., Matsen J.P., Sorensen J.B., et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol 2009, 20:1660-1666.
37. Kim Y.I. Role of the MTHFR polymorphisms in cancer risk modification and treatment. Future Oncol 2009, 5:523-542.
38. De Chaudhuri S., Mahata J., Das J.K., Mukherjee A., Ghosh P., Sau T.J., et al. Association of specific p53 polymorphisms with keratosis in individuals exposed to arsenic through drinking water in West Bengal, India. Mutat Res 2006, 601:102-112.
39. Rosell R., Gonzalez-Larriba J.L., Alberola V., Molina F., Monzo M., Benito D., et al. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity. Semin Oncol 1995, 22:12-18.
40. Lee J.M., Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci U S A 1993, 90:5742-5746.
41. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher D.E., et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266:807-810.
42. Khrunin A.V., Moisseev A., Gorbunova V., Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 2010, 10:54-61.
43. Brody J.R., Hucl T., Costantino C.L., Eshleman J.R., Gallmeier E., Zhu H., et al. Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence. Cancer Res 2009, 69:984-991.
44. Marsh S., Paul J., King C.R., Gifford G., McLeod H.L., Brown R. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol 2007, 25:4528-4535.